Literature DB >> 30189015

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?

Alexander Amberg1, Lennart T Anger1, Joel Bercu2, David Bower3, Kevin P Cross3, Laura Custer4, James S Harvey5, Catrin Hasselgren6, Masamitsu Honma7, Candice Johnson3, Robert Jolly8, Michelle O Kenyon9, Naomi L Kruhlak10, Penny Leavitt4, Donald P Quigley3, Scott Miller3, David Snodin11, Lidiya Stavitskaya10, Andrew Teasdale12, Alejandra Trejo-Martin12, Angela T White5, Joerg Wichard13, Glenn J Myatt3.   

Abstract

(Quantitative) structure-activity relationship or (Q)SAR predictions of DNA-reactive mutagenicity are important to support both the design of new chemicals and the assessment of impurities, degradants, metabolites, extractables and leachables, as well as existing chemicals. Aromatic N-oxides represent a class of compounds that are often considered alerting for mutagenicity yet the scientific rationale of this structural alert is not clear and has been questioned. Because aromatic N-oxide-containing compounds may be encountered as impurities, degradants and metabolites, it is important to accurately predict mutagenicity of this chemical class. This article analysed a series of publicly available aromatic N-oxide data in search of supporting information. The article also used a previously developed structure-activity relationship (SAR) fingerprint methodology where a series of aromatic N-oxide substructures was generated and matched against public and proprietary databases, including pharmaceutical data. An assessment of the number of mutagenic and non-mutagenic compounds matching each substructure across all sources was used to understand whether the general class or any specific subclasses appear to lead to mutagenicity. This analysis resulted in a downgrade of the general aromatic N-oxide alert. However, it was determined there were enough public and proprietary data to assign the quindioxin and related chemicals as well as benzo[c][1,2,5]oxadiazole 1-oxide subclasses as alerts. The overall results of this analysis were incorporated into Leadscope's expert-rule-based model to enhance its predictive accuracy.
© The Author(s) 2018. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30189015      PMCID: PMC6402318          DOI: 10.1093/mutage/gey020

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  42 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52.

Authors:  Tatiana I Netzeva; Andrew Worth; Tom Aldenberg; Romualdo Benigni; Mark T D Cronin; Paolo Gramatica; Joanna S Jaworska; Scott Kahn; Gilles Klopman; Carol A Marchant; Glenn Myatt; Nina Nikolova-Jeliazkova; Grace Y Patlewicz; Roger Perkins; David Roberts; Terry Schultz; David W Stanton; Johannes J M van de Sandt; Weida Tong; Gilman Veith; Chihae Yang
Journal:  Altern Lab Anim       Date:  2005-04       Impact factor: 1.303

3.  1- and 3-nitro-6-azabenzo[a]pyrenes and their N-oxides: highly mutagenic nitrated azaarenes.

Authors:  K Fukuhara; A Hakura; N Sera; H Tokiwa; N Miyata
Journal:  Chem Res Toxicol       Date:  1992 Mar-Apr       Impact factor: 3.739

4.  Critique of carcinogenic mechanism.

Authors:  W NAKAHARA
Journal:  Prog Exp Tumor Res       Date:  1961

5.  Mutagenic evaluation of some triazino indoles using the Salmonella/mammalian microsome assay.

Authors:  A Lopez-de-Cerain; E García; A Gullón; J I Recalde; A Monge
Journal:  Mutagenesis       Date:  1990-07       Impact factor: 3.000

6.  DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditions.

Authors:  Goutam Chowdhury; Ujjal Sarkar; Susan Pullen; William R Wilson; Anuruddha Rajapakse; Tarra Fuchs-Knotts; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2011-11-22       Impact factor: 3.739

7.  Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP.

Authors:  J Ashby; R W Tennant
Journal:  Mutat Res       Date:  1991-05       Impact factor: 2.433

Review 8.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009

9.  4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species.

Authors:  Yaeno Arima; Chikako Nishigori; Toru Takeuchi; Shigenori Oka; Kanehisa Morimoto; Atsushi Utani; Yoshiki Miyachi
Journal:  Toxicol Sci       Date:  2006-03-17       Impact factor: 4.849

10.  Database resources of the National Center for Biotechnology Information.

Authors:  David L Wheeler; Tanya Barrett; Dennis A Benson; Stephen H Bryant; Kathi Canese; Deanna M Church; Michael DiCuccio; Ron Edgar; Scott Federhen; Wolfgang Helmberg; David L Kenton; Oleg Khovayko; David J Lipman; Thomas L Madden; Donna R Maglott; James Ostell; Joan U Pontius; Kim D Pruitt; Gregory D Schuler; Lynn M Schriml; Edwin Sequeira; Steven T Sherry; Karl Sirotkin; Grigory Starchenko; Tugba O Suzek; Roman Tatusov; Tatiana A Tatusova; Lukas Wagner; Eugene Yaschenko
Journal:  Nucleic Acids Res       Date:  2005-01-01       Impact factor: 16.971

View more
  1 in total

1.  Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updates.

Authors:  Catrin Hasselgren; Joel Bercu; Alex Cayley; Kevin Cross; Susanne Glowienke; Naomi Kruhlak; Wolfgang Muster; John Nicolette; M Vijayaraj Reddy; Roustem Saiakhov; Krista Dobo
Journal:  Regul Toxicol Pharmacol       Date:  2020-10-13       Impact factor: 3.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.